July 6, 2022

Harpoon Therapeutics Expands Leadership Team

  • Appointments named for two key executive leadership positions in human resources and translational medicine

SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine. Both Ms. Chang and Dr. Anand bring deep experience to their respective roles, enhancing strategic and scientific guidance within the organization to drive the company forward in a year of anticipated clinical advancements across Harpoon’s portfolio.

Ms. Chang has over 20 years of human resources experience in life sciences and an extensive background in aligning talent with organizations’ overall vision and direction. She comes to Harpoon from IDbyDNA where she served as Vice President, Head of People & Culture. She previously served as Vice President, Human Resources at Gilead Sciences and, earlier in her career, at Bio-Rad Laboratories.

Dr. Anand brings more than 18 years of experience leading translational research and implementing drug discovery and development strategies for unmet medical needs across multiple therapeutic areas and clinical modalities. Prior to joining Harpoon, Dr. Anand served as Vice President, Head of Nonclinical Development/Clinical Pharmacology at Molecular Templates. He previously served in multiple leadership and scientific roles at NantKwest, Astellas (Agensys) and Genentech.

“We are pleased to welcome Wendy and Banmeet to the Harpoon leadership team,” said Julie Eastland, President and CEO of Harpoon Therapeutics. “It is exciting to have an HR leader of Wendy’s caliber onboard as we continue to evolve as an organization. Additionally, I am confident Banmeet’s breadth of translational medicine experience and ability to successfully lead development teams will provide critical value as we look to advance our multiple T cell engager programs.”

About Harpoon Therapeutics 

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “look forward,” “plan,” “target,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the development and advancement of Harpoon Therapeutics’ platforms and product candidates, including progress, timing, planned milestones, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics’ cash resources. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in Harpoon Therapeutics’ annual report on Form 10-K for the month ended March 31, 2022 and other filings by Harpoon Therapeutics. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.


Robert Uhl
ICR Westwicke

uncapped communications

Georgia Erbez
Chief Financial Officer

Primary Logo

Source: Harpoon Therapeutics

Search Investor Relations